Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size
- PMID: 25501076
- PMCID: PMC4602780
- DOI: 10.1097/MD.0000000000000203
Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size
Abstract
Insufficient data are available regarding the validation of long-term survival in patients with T2 (solitary tumor with microvascular invasion [MVI] or multiple tumors, none >5 cm) hepatocellular carcinoma (HCC) after primary hepatectomy. We aim to evaluate the survival and relevant risk factors for T2 HCC patients. Between 2001 and 2007, 312 T2 HCC patients who underwent primary hepatectomy were included. Survival was estimated using the Kaplan-Meier method and compared using Cox proportional hazard model with adjusted independent prognostic factors. The 1, 3, and 5-year overall survival rates of patients with MVI were 85.7%, 68.7%, and 64.8%, respectively; these were inferior to the rates in patients without MVI, which were 93.0%, 89.3%, and 73.7%, respectively (P = 0.037). Within the with-MVI group, the survival rate of patients with tumor sizes ≥ 5 cm was inferior to that of patients with tumors <5 cm (overall, P = 0.01; recurrence-free, P < 0.0001). For patients with the largest tumors in the <5-cm group, those without MVI tended to have a higher probability of recurrence for 2 years after resection (P = 0.088) but a similar overall survival rate relative to those with MVI (P = 0.31). The crude metastasis-free survival was higher in the without-MVI group than in the with-MVI group (P = 0.012). The T2 HCC category comprised heterogeneous patients with differences in survival rates. Extrahepatic recurrence occurred more frequently in patients with MVI than in those without MVI. These results provide evidence for an updated definition of T2 HCC.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures




Similar articles
-
The significance of classifying microvascular invasion in patients with hepatocellular carcinoma.Ann Surg Oncol. 2014 Mar;21(3):1002-9. doi: 10.1245/s10434-013-3376-9. Epub 2013 Nov 20. Ann Surg Oncol. 2014. PMID: 24254204
-
The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients.J Gastrointest Surg. 2015 Jul;19(7):1281-90. doi: 10.1007/s11605-015-2849-5. Epub 2015 May 9. J Gastrointest Surg. 2015. PMID: 25956724
-
Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.Ann Surg Oncol. 2008 May;15(5):1375-82. doi: 10.1245/s10434-008-9846-9. Epub 2008 Mar 7. Ann Surg Oncol. 2008. PMID: 18324443
-
Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis.HPB (Oxford). 2019 Aug;21(8):935-944. doi: 10.1016/j.hpb.2019.02.003. Epub 2019 Mar 11. HPB (Oxford). 2019. PMID: 30871805
-
Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma.J Gastroenterol Hepatol. 2018 Feb;33(2):347-354. doi: 10.1111/jgh.13843. J Gastroenterol Hepatol. 2018. PMID: 28589639 Review.
Cited by
-
Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2023 Jan 30;10:123-138. doi: 10.2147/JHC.S385238. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36741246 Free PMC article.
-
Nomograms to Predict the Individual Survival of Patients with Solitary Hepatocellular Carcinoma after Hepatectomy.Gut Liver. 2017 Sep 15;11(5):684-692. doi: 10.5009/gnl16465. Gut Liver. 2017. PMID: 28651303 Free PMC article.
-
Wls Expression Correlates with Tumor Differentiation and TNM Stage in Hepatocellular Carcinoma.Dig Dis Sci. 2018 Jan;63(1):166-172. doi: 10.1007/s10620-017-4823-4. Epub 2017 Nov 10. Dig Dis Sci. 2018. PMID: 29127606
-
Ultrasound Patterns of Hepatocellular Carcinoma and Their Prognostic Impact: A Retrospective Study.Cancers (Basel). 2023 Nov 13;15(22):5396. doi: 10.3390/cancers15225396. Cancers (Basel). 2023. PMID: 38001656 Free PMC article.
-
MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53.Oncogenesis. 2019 Nov 15;8(12):67. doi: 10.1038/s41389-019-0176-5. Oncogenesis. 2019. PMID: 31732712 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx Accessed June 2014.
-
- Ho CM, Lee PH, Chen CL, et al. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol 2012; 19:826–833. - PubMed
-
- Ho CM, Lee PH, Shau WY, et al. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery 2012; 151:700–709. - PubMed
-
- EI-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118–1127. - PubMed
-
- Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141:330–339. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical